- Petrelintide achieved up to 10.7% mean weight reduction at week 42 versus 1.7% with placebo.
- The Phase II ZUPREME-1 trial involved 493 participants with a mean BMI of 37 kg/m².
- No vomiting cases or treatment discontinuations due to gastrointestinal issues at the effective dose.
- ZUPREME-2 results expected in the second half of 2026; combination trial with CT-388 to start later in 2026.
Trial Results
Roche's Phase II ZUPREME-1 trial for petrelintide, an amylin analog, showed promising results in weight management for individuals with overweight and obesity. The trial involved 493 participants with a mean BMI of 37 kg/m². Petrelintide achieved up to 10.7% mean body weight reduction at week 42, compared to 1.7% with placebo, demonstrating significant efficacy.
Tolerability and Safety
Petrelintide exhibited a favorable tolerability profile, comparable to placebo, with no unexpected safety signals. The treatment discontinuation rate due to adverse events was 4.8% for petrelintide versus 4.9% for placebo. Gastrointestinal-related adverse events were mostly mild, with no vomiting cases in the maximally effective treatment arm.
Future Developments
The trial's findings support further development of petrelintide for chronic weight management, both as monotherapy and in combination with other treatments. The ZUPREME-2 trial, evaluating petrelintide in individuals with obesity or overweight and type 2 diabetes, is expected to release results in the second half of 2026. Additionally, a Phase II trial exploring the combination of petrelintide and CT-388 is planned for later in 2026.
Obesity Context
Obesity is a major global health concern, projected to affect over four billion people by 2035. This trend is driven by a mix of genetic, biological, behavioral, environmental, and socioeconomic factors, increasing the burden on healthcare systems due to associated comorbidities and reduced quality of life.
